ReEmerge
ReEmerge is developing Cognitive Network Restoration Therapy (CNRT), an investigational deep brain stimulation approach that targets disrupted neural circuits to restore cognitive function in patients with traumatic brain injury. The therapy aims to reverse cognitive deficits rather than merely help patients compensate, with clinical evidence from a Phase 1 randomized feasibility study of central thalamic DBS in TBI.
- Medical Devices
- Healthcare Technology
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Approximately 27 million people worldwide experience traumatic brain injury (TBI) each year, and many are left with persistent cognitive impairment. Current treatment focuses on rehabilitation over extended periods, helping patients compensate for cognitive deficits through structured routines and adaptive strategies, but recovery often plateaus, leaving patients with lasting impairments that limit independence and quality of life.
Solution
ReEmerge is pioneering Cognitive Network Restoration Therapy (CNRT), an innovative investigational therapy that precisely targets disrupted neural networks caused by TBI. By delivering central thalamic deep brain stimulation, CNRT aims to drive underactive but viable neural circuits back to functional levels, reversing cognitive deficits rather than merely helping patients compensate for them. The therapy is designed to restore function to existing but underperforming networks, with the goal of restoring agency and personhood for patients who have plateaued under conventional rehabilitation approaches.
Target Audience
Primary customers are patients with persistent cognitive impairment following traumatic brain injury, along with the neurologists, neurosurgeons, and rehabilitation centers that treat them.
Features
- Central thalamic deep brain stimulation targeting neural network disruptions caused by traumatic brain injury
- Cognitive Network Restoration Therapy (CNRT) designed to activate underactive but viable neural circuits
- Clinical evidence base including a Phase 1 randomized feasibility study of thalamic deep brain stimulation in TBI
- Research publications covering subject and family perspectives and improved autobiographical memory outcomes from central thalamic DBS studies
- Investigational device status under U.S. federal law, limited to investigational use and not yet approved for commercial use